Endometrial Cancer

1. Front Matter

   Pages i-xiv

   PDF

2. Epidemiology of endometrial cancer

   • Lynda F. Voigt, Noel S. Weiss

   Pages 1-21

3. Surgical management of endometrial cancer

   • Gerard Wain, C. Paul Morrow

   Pages 23-40

4. Peritoneal cytology in endometrial carcinoma

   • Gregory P. Sutton

   Pages 41-52

5. The role of preoperative radiotherapy in the treatment of carcinoma of the endometrium

   • Nina Einhorn

   Pages 53-61

6. Radiotherapy in the management of nodal and peritoneal metastases

   • Roger A. Potish

   Pages 63-70

7. Carcinoma of the endometrium and hormonal receptors

   • P. G. Satyaswaroop, R. J. Zaino, R. Mortel

   Pages 71-92

8. Systemic therapy with single agents for advanced or recurrent endometrial carcinoma

   • Tate Thigpen

   Pages 93-106

9. Multiagent chemotherapy of endometrial carcinoma

   • Dean E. Brenner

   Pages 107-116

10. In vitro sensitivity of human endometrial cancer to cytotoxic and biologic agents

    • Charles E. Welander, Charles M. Jones III, David S. Alberts, Sydney E. Salmon

    Pages 117-126

11. Back Matter

    Pages 127-131

    PDF

The incidence of endometrial cancer rose sharply in the United States in the early 1970s, paralleling changes in the use of postmenopausal estrogens by American women. A sizeable body of evidence supports the role of both excessive endogenous estrogen and exogenous estrogen in the etiology of endometrial cancer. There is growing evidence that inadequate progesterone has the opposite effect, in that progesterone supplementation of postmeno­ pausal estrogen therapy reduces the incidence of endometrial cancer. Despite this new awareness of the hormonal role that is played in carcino­ ma of the endometrium, the disease still plagues the oncologist. The general approach to carcinoma of the endometrium in the United States is that of primary surgical staging. This provides the maximum amount of information to best plan postoperative radiation therapy and/or chemotherapy for these patients. In general, patients who are considered candidates for surgical staging are those with advanced disease or high-risk stage I endometrial carcinoma. High-risk endometrial carcinoma is defined as those patients with moderately differentiated lesions with deep myometrial invasion, poor­ ly differentiated carcinoma of the endometrium, and the high-risk histolo­ gies such as papillary carcinoma and clear-cell carcinomas. The surgical staging has extended in most institutions to patients with occult stage II carcinoma of the endometrium, i. e.

• Staging
• cancer
• carcinoma
• chemotherapy
• endometrium
• oncology
• radiation therapy
• surgical oncology

`I recommend this book to physicians, especially gynaecologic and medical oncologists who would like to have a comprehensive summary of new aspects in the management of endometrial cancer.'
M. Kaufmann, Annals of Oncology, 1990

• Southern Arizona Surgical Oncology, Ltd, Tucson, USA

  Earl A. Surwit

• College of Medicine, University of Arizona, Tucson, USA

  David S. Alberts

Policies and ethics